NCT04825873

A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China

The Observational Safety Study for Nivolumab in China Routine Oncology Practice

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,102 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety of nivolumab in routine cancer practice in China. Part one of the study will investigate nivolumab for non-small cell lung cancer previously treated with platinum-based chemotherapy that has locally advanced or has spread. Part two will investigate nivolumab for post-platinum squamous cell carcinoma of head and neck that is recurrent or has spread. Part three will investigate nivolumab for locally advanced or metastatic non-small cell lung cancer. Part four will investigate nivolumab for recurrent or metastatic squamous cell carcinoma of head and neck.

Conditions

• Non-Small Cell Lung Cancer
• Squamous Cell Carcinoma of Head and Neck

Timeline

• Start date: 2021-05-28
• Primary completion: 2023-02-13
• Completion: 2023-02-13
• First posted: 2021-04-01
• Last updated: 2023-10-13

Locations

2 sites across 1 country: China